Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
NCT03785145 is registered in ClinicalTrials.gov with Medy-Tox as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
- Lead sponsor
- Medy-Tox
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 20, 2018
- Completion date
- January 25, 2021
- Enrollment
- 235 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
lateral canthal lines